<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02660489</url>
  </required_header>
  <id_info>
    <org_study_id>ORCA2015</org_study_id>
    <nct_id>NCT02660489</nct_id>
  </id_info>
  <brief_title>Effect of OC459 on the Response to Rhinovirus Challenge in Asthma</brief_title>
  <official_title>Effect of the CRTH2 Antagonist OC459 on the Response to Rhinovirus Challenge in Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Atopix Therapeutics, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess the effectiveness of a CRTH2 receptor antagonist, OC459,&#xD;
      in preventing or attenuating the worsening of asthma symptoms during rhinovirus infection.&#xD;
      The study is a double blind, randomised trial in which half the subjects will receive OC459&#xD;
      and the other half placebo, before being inoculated with rhinovirus, that would normally&#xD;
      induce a worsening of asthma symptoms i.e. an exacerbation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Asthma is the most common chronic respiratory disease, and in many countries prevalence is&#xD;
      rising. The major morbidity, mortality and health care costs related to asthma are a result&#xD;
      of periods of acutely increased symptomatology called 'exacerbations'. Most exacerbations are&#xD;
      caused by rhinovirus, the virus associated with the common cold. There are few treatments to&#xD;
      prevent and treat exacerbations, and despite these &gt;50% of adult asthmatics reported having&#xD;
      an exacerbation in the last year. There is therefore a major unmet need.&#xD;
&#xD;
      Experimentally inoculating patients with asthma with rhinovirus, a methodology that has been&#xD;
      safely used for &gt;15 years, induces an infection and worsening symptoms in ~85%. This model&#xD;
      offers the possibility to investigate treatment effects on asthma exacerbations with a small&#xD;
      number of subjects, minimising the numbers exposed to a novel drug with limited safety data.&#xD;
      In contrast, trials of therapies powered to evaluate an effect on naturally occurring&#xD;
      exacerbations require several hundred subjects, a long study period to capture enough events,&#xD;
      and are significantly more expensive to carry out.&#xD;
&#xD;
      Using this model the investigators have shown that several inflammatory molecules, including&#xD;
      prostaglandin D2 (PGD2), are significantly increased during rhinovirus-induced asthma&#xD;
      exacerbations, with the levels of PGD2 strongly correlating with the severity of the&#xD;
      symptoms. Moreover other studies have shown that when PGD2 binds the CRTH2 receptor, it&#xD;
      stimulates the release of a number of inflammatory molecules also associated with asthma&#xD;
      exacerbations. Blocking the CRTH2 receptor therefore appears an extremely promising target&#xD;
      with potential to limit the virus-induced inflammation underpinning many asthma&#xD;
      exacerbations.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2015</start_date>
  <completion_date type="Actual">February 2018</completion_date>
  <primary_completion_date type="Actual">February 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Lower Respiratory Symptom Score</measure>
    <time_frame>During 14 days following rhinovirus inoculation</time_frame>
    <description>Sum of daily scores for 14 days. Seven symptoms (cough on waking, wheeze on waking, daytime cough, daytime wheeze, daytime chest tightness, daytime breathlessness, nocturnal cough/wheeze/breathlessness) ranked from 0 (none) to 3 (severe). Range 0 to 294; higher is more symptomatic.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Asthma Control Questionnaire (ACQ)-6 Score</measure>
    <time_frame>Baseline, 10 days post rhinovirus inoculation</time_frame>
    <description>Change from baseline (rhinovirus inoculation, day 0) to day 10. The ACQ was developed to measure the adequacy of asthma control in clinical research and in clinical practice. The ACQ-6 asks subjects to grade their asthma control, assessed through six questions, over the previous seven days. Each question is rated on a seven-point scale ranging from 0 (well controlled) to six (extremely poorly controlled). The ACQ-6 score is the mean of the scores on the 6 items. Mean scores of =&lt;0.75 indicate well-controlled asthma, scores between 0.76 and &lt; 1.5 indicate partly controlled asthma, and a score &gt;= 1.5 indicates uncontrolled asthma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change in Peak Expiratory Flow Rate</measure>
    <time_frame>Baseline and up to 14 days post rhinovirus inoculation</time_frame>
    <description>Percentage change from baseline (rhinovirus inoculation, day 0) to trough during infection (up to day 14)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Forced Expiratory Volume in 1 Second (FEV1)</measure>
    <time_frame>Baseline and up to 14 days post rhinovirus inoculation</time_frame>
    <description>Percentage change from baseline (rhinovirus inoculation, day 0) to trough during infection (up to day 14)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Exhaled Nitric Oxide (FeNO)</measure>
    <time_frame>Baseline and up to 10 days post rhinovirus inoculation</time_frame>
    <description>Percentage change from baseline (rhinovirus inoculation, day 0) to peak during infection (highest of measurements on days 3, 5, 7, 10 post inoculation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Airway Hyper Responsiveness (Histamine)</measure>
    <time_frame>Baseline and 7 days post rhinovirus inoculation</time_frame>
    <description>Assessed as the provocation concentration of histamine producing a 20% fall in FEV1, or PC20 Change from baseline (rhinovirus inoculation, day 0) to day 7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral Load (in Nasal Lavage Samples)</measure>
    <time_frame>Up to 14 days post rhinovirus inoculation</time_frame>
    <description>Peak during infection (up to day 14)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Upper Respiratory Symptom Score</measure>
    <time_frame>During 14 days following rhinovirus inoculation</time_frame>
    <description>Sum of daily scores for 14 days. Eight upper respiratory symptoms (sneezing; runny nose; blocked or stuffy nose; sore throat or hoarse voice; headache or face pain; generally unwell; chill, fever or shivery; cough) ranked from 0 (none) to 3 (severe). Range 0 to 336; higher is more symptomatic.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Asthma</condition>
  <condition>Rhinovirus</condition>
  <condition>Picornaviridae Infections</condition>
  <condition>Common Cold</condition>
  <arm_group>
    <arm_group_label>OC459 (CRTH2 antagonist)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OC459 50mg once daily for 5 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet once daily for 5 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OC459</intervention_name>
    <arm_group_label>OC459 (CRTH2 antagonist)</arm_group_label>
    <other_name>OC000459</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Rhinovirus</intervention_name>
    <description>Inoculation with rhinovirus serotype 16</description>
    <arm_group_label>OC459 (CRTH2 antagonist)</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18--55 years&#xD;
&#xD;
          -  Male or female&#xD;
&#xD;
          -  Clinical diagnosis of asthma for at least 6 months prior to screening&#xD;
&#xD;
          -  An Asthma Control Questionnaire (ACQ) Score &gt;0.75&#xD;
&#xD;
          -  Positive histamine challenge test (PC20 &lt;8 µg/ml, or &lt;12 µg/ml and bronchodilator&#xD;
             response ≥ 12%)&#xD;
&#xD;
          -  Worsening asthma symptoms with infection since last change in asthma therapy&#xD;
&#xD;
          -  Positive skin prick test to common aeroallergens (e.g. animal epithelia, dust mite)&#xD;
&#xD;
          -  Treatment comprising inhaled corticosteroids (ICS) or combination inhaler (Long&#xD;
             -Acting Beta Agonist with ICS), with a daily ICS dose of at least 100mcg fluticasone&#xD;
             or equivalent.&#xD;
&#xD;
          -  Participant is willing for their GP to be informed of their participation.&#xD;
&#xD;
          -  English speaker&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of clinically significant diseases other than asthma, which, in the opinion&#xD;
             of the investigator, may either put the patient at risk because of participation in&#xD;
             the trial, or diseases which may influence the results of the study or the patient's&#xD;
             ability to take part in it&#xD;
&#xD;
          -  Smoking history over past 12 months&#xD;
&#xD;
          -  Seasonal allergic rhinitis symptoms at screening&#xD;
&#xD;
          -  Asthma exacerbation or viral illness within the previous 6 weeks&#xD;
&#xD;
          -  Current or concomitant use of oral steroids, anti--leukotrienes or monoclonal&#xD;
             antibodies&#xD;
&#xD;
          -  Pregnant or breast-feeding women (patients should not be enrolled if they plan to&#xD;
             become pregnant during the time of study participation)&#xD;
&#xD;
          -  Contact with infants &lt;6 months or immunocompromised persons, elderly and infirm at&#xD;
             home or at work&#xD;
&#xD;
          -  Subjects who have known evidence of lack of adherence to medications and/or ability to&#xD;
             follow physician's recommendations&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sebastian L Johnston, MBBS PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Heart &amp; Lung Institute, Imperial College London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St Mary's Hospital</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>W2 1PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 12, 2016</study_first_submitted>
  <study_first_submitted_qc>January 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2016</study_first_posted>
  <results_first_submitted>December 10, 2019</results_first_submitted>
  <results_first_submitted_qc>February 9, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 26, 2021</results_first_posted>
  <last_update_submitted>February 9, 2021</last_update_submitted>
  <last_update_submitted_qc>February 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CRTH2 antagonist</keyword>
  <keyword>Prostaglandin D2 receptor</keyword>
  <keyword>Anti-Asthmatic Agents</keyword>
  <keyword>OC459</keyword>
  <keyword>Allergic asthma</keyword>
  <keyword>Eosinophilia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Common Cold</mesh_term>
    <mesh_term>Picornaviridae Infections</mesh_term>
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 4, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/89/NCT02660489/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 13, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/89/NCT02660489/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>OC459 (CRTH2 Antagonist)</title>
          <description>OC459 50mg once daily for 5 weeks&#xD;
Rhinovirus: Inoculation with rhinovirus serotype 16</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo tablet once daily for 5 weeks&#xD;
Rhinovirus: Inoculation with rhinovirus serotype 16</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16">Completed with confirmed rhinovirus infection</participants>
                <participants group_id="P2" count="14">Completed with confirmed rhinovirus infection</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>no rhinovirus infection</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Participants who completed the study and had confirmed rhinovirus infection</population>
      <group_list>
        <group group_id="B1">
          <title>OC459 (CRTH2 Antagonist)</title>
          <description>OC459 50mg once daily for 5 weeks&#xD;
Rhinovirus: Inoculation with rhinovirus serotype 16</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo tablet once daily for 5 weeks&#xD;
Rhinovirus: Inoculation with rhinovirus serotype 16</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="16"/>
                    <count group_id="B2" value="14"/>
                    <count group_id="B3" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.3" spread="8.9"/>
                    <measurement group_id="B2" value="25.4" spread="3.8"/>
                    <measurement group_id="B3" value="25.3" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="16"/>
                    <count group_id="B2" value="14"/>
                    <count group_id="B3" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Lower Respiratory Symptom Score</title>
        <description>Sum of daily scores for 14 days. Seven symptoms (cough on waking, wheeze on waking, daytime cough, daytime wheeze, daytime chest tightness, daytime breathlessness, nocturnal cough/wheeze/breathlessness) ranked from 0 (none) to 3 (severe). Range 0 to 294; higher is more symptomatic.</description>
        <time_frame>During 14 days following rhinovirus inoculation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OC459 (CRTH2 Antagonist)</title>
            <description>OC459 50mg once daily for 5 weeks&#xD;
Rhinovirus: Inoculation with rhinovirus serotype 16</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo tablet once daily for 5 weeks&#xD;
Rhinovirus: Inoculation with rhinovirus serotype 16</description>
          </group>
        </group_list>
        <measure>
          <title>Total Lower Respiratory Symptom Score</title>
          <description>Sum of daily scores for 14 days. Seven symptoms (cough on waking, wheeze on waking, daytime cough, daytime wheeze, daytime chest tightness, daytime breathlessness, nocturnal cough/wheeze/breathlessness) ranked from 0 (none) to 3 (severe). Range 0 to 294; higher is more symptomatic.</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21" lower_limit="13.3" upper_limit="46.5"/>
                    <measurement group_id="O2" value="18" lower_limit="9.8" upper_limit="51.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.78</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Asthma Control Questionnaire (ACQ)-6 Score</title>
        <description>Change from baseline (rhinovirus inoculation, day 0) to day 10. The ACQ was developed to measure the adequacy of asthma control in clinical research and in clinical practice. The ACQ-6 asks subjects to grade their asthma control, assessed through six questions, over the previous seven days. Each question is rated on a seven-point scale ranging from 0 (well controlled) to six (extremely poorly controlled). The ACQ-6 score is the mean of the scores on the 6 items. Mean scores of =&lt;0.75 indicate well-controlled asthma, scores between 0.76 and &lt; 1.5 indicate partly controlled asthma, and a score &gt;= 1.5 indicates uncontrolled asthma.</description>
        <time_frame>Baseline, 10 days post rhinovirus inoculation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OC459 (CRTH2 Antagonist)</title>
            <description>OC459 50mg once daily for 5 weeks&#xD;
Rhinovirus: Inoculation with rhinovirus serotype 16</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo tablet once daily for 5 weeks&#xD;
Rhinovirus: Inoculation with rhinovirus serotype 16</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Asthma Control Questionnaire (ACQ)-6 Score</title>
          <description>Change from baseline (rhinovirus inoculation, day 0) to day 10. The ACQ was developed to measure the adequacy of asthma control in clinical research and in clinical practice. The ACQ-6 asks subjects to grade their asthma control, assessed through six questions, over the previous seven days. Each question is rated on a seven-point scale ranging from 0 (well controlled) to six (extremely poorly controlled). The ACQ-6 score is the mean of the scores on the 6 items. Mean scores of =&lt;0.75 indicate well-controlled asthma, scores between 0.76 and &lt; 1.5 indicate partly controlled asthma, and a score &gt;= 1.5 indicates uncontrolled asthma.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.68"/>
                    <measurement group_id="O2" value="0.17" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.49</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change in Peak Expiratory Flow Rate</title>
        <description>Percentage change from baseline (rhinovirus inoculation, day 0) to trough during infection (up to day 14)</description>
        <time_frame>Baseline and up to 14 days post rhinovirus inoculation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OC459 (CRTH2 Antagonist)</title>
            <description>OC459 50mg once daily for 5 weeks&#xD;
Rhinovirus: Inoculation with rhinovirus serotype 16</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo tablet once daily for 5 weeks&#xD;
Rhinovirus: Inoculation with rhinovirus serotype 16</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in Peak Expiratory Flow Rate</title>
          <description>Percentage change from baseline (rhinovirus inoculation, day 0) to trough during infection (up to day 14)</description>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.9" spread="10.2"/>
                    <measurement group_id="O2" value="-13.1" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.50</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Forced Expiratory Volume in 1 Second (FEV1)</title>
        <description>Percentage change from baseline (rhinovirus inoculation, day 0) to trough during infection (up to day 14)</description>
        <time_frame>Baseline and up to 14 days post rhinovirus inoculation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OC459 (CRTH2 Antagonist)</title>
            <description>OC459 50mg once daily for 5 weeks&#xD;
Rhinovirus: Inoculation with rhinovirus serotype 16</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo tablet once daily for 5 weeks&#xD;
Rhinovirus: Inoculation with rhinovirus serotype 16</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Forced Expiratory Volume in 1 Second (FEV1)</title>
          <description>Percentage change from baseline (rhinovirus inoculation, day 0) to trough during infection (up to day 14)</description>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.5" spread="11.3"/>
                    <measurement group_id="O2" value="-12.7" spread="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.36</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Exhaled Nitric Oxide (FeNO)</title>
        <description>Percentage change from baseline (rhinovirus inoculation, day 0) to peak during infection (highest of measurements on days 3, 5, 7, 10 post inoculation)</description>
        <time_frame>Baseline and up to 10 days post rhinovirus inoculation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OC459 (CRTH2 Antagonist)</title>
            <description>OC459 50mg once daily for 5 weeks&#xD;
Rhinovirus: Inoculation with rhinovirus serotype 16</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo tablet once daily for 5 weeks&#xD;
Rhinovirus: Inoculation with rhinovirus serotype 16</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Exhaled Nitric Oxide (FeNO)</title>
          <description>Percentage change from baseline (rhinovirus inoculation, day 0) to peak during infection (highest of measurements on days 3, 5, 7, 10 post inoculation)</description>
          <units>percentage change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58" lower_limit="27" upper_limit="101"/>
                    <measurement group_id="O2" value="23" lower_limit="0" upper_limit="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.12</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Airway Hyper Responsiveness (Histamine)</title>
        <description>Assessed as the provocation concentration of histamine producing a 20% fall in FEV1, or PC20 Change from baseline (rhinovirus inoculation, day 0) to day 7</description>
        <time_frame>Baseline and 7 days post rhinovirus inoculation</time_frame>
        <population>Two subjects (one from each group) were unable to complete PC20 at one of the time points for logistical reasons</population>
        <group_list>
          <group group_id="O1">
            <title>OC459 (CRTH2 Antagonist)</title>
            <description>OC459 50mg once daily for 5 weeks&#xD;
Rhinovirus: Inoculation with rhinovirus serotype 16</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo tablet once daily for 5 weeks&#xD;
Rhinovirus: Inoculation with rhinovirus serotype 16</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Airway Hyper Responsiveness (Histamine)</title>
          <description>Assessed as the provocation concentration of histamine producing a 20% fall in FEV1, or PC20 Change from baseline (rhinovirus inoculation, day 0) to day 7</description>
          <population>Two subjects (one from each group) were unable to complete PC20 at one of the time points for logistical reasons</population>
          <units>mg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" lower_limit="-0.77" upper_limit="0.21"/>
                    <measurement group_id="O2" value="-0.64" lower_limit="-2.19" upper_limit="-0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.12</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Viral Load (in Nasal Lavage Samples)</title>
        <description>Peak during infection (up to day 14)</description>
        <time_frame>Up to 14 days post rhinovirus inoculation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OC459 (CRTH2 Antagonist)</title>
            <description>OC459 50mg once daily for 5 weeks&#xD;
Rhinovirus: Inoculation with rhinovirus serotype 16</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo tablet once daily for 5 weeks&#xD;
Rhinovirus: Inoculation with rhinovirus serotype 16</description>
          </group>
        </group_list>
        <measure>
          <title>Viral Load (in Nasal Lavage Samples)</title>
          <description>Peak during infection (up to day 14)</description>
          <units>viral copies / mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="445861" lower_limit="0" upper_limit="9025667"/>
                    <measurement group_id="O2" value="215782" lower_limit="0" upper_limit="25240371"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.75</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Upper Respiratory Symptom Score</title>
        <description>Sum of daily scores for 14 days. Eight upper respiratory symptoms (sneezing; runny nose; blocked or stuffy nose; sore throat or hoarse voice; headache or face pain; generally unwell; chill, fever or shivery; cough) ranked from 0 (none) to 3 (severe). Range 0 to 336; higher is more symptomatic.</description>
        <time_frame>During 14 days following rhinovirus inoculation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OC459 (CRTH2 Antagonist)</title>
            <description>OC459 50mg once daily for 5 weeks&#xD;
Rhinovirus: Inoculation with rhinovirus serotype 16</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo tablet once daily for 5 weeks&#xD;
Rhinovirus: Inoculation with rhinovirus serotype 16</description>
          </group>
        </group_list>
        <measure>
          <title>Total Upper Respiratory Symptom Score</title>
          <description>Sum of daily scores for 14 days. Eight upper respiratory symptoms (sneezing; runny nose; blocked or stuffy nose; sore throat or hoarse voice; headache or face pain; generally unwell; chill, fever or shivery; cough) ranked from 0 (none) to 3 (severe). Range 0 to 336; higher is more symptomatic.</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33" lower_limit="20.5" upper_limit="63.3"/>
                    <measurement group_id="O2" value="41" lower_limit="18.5" upper_limit="63.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.66</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>9 weeks</time_frame>
      <desc>Participants were asked to record adverse events in a study diary that was completed daily.&#xD;
Participants were also asked about adverse events at study visits.</desc>
      <group_list>
        <group group_id="E1">
          <title>OC459 (CRTH2 Antagonist)</title>
          <description>OC459 50mg once daily for 5 weeks&#xD;
Rhinovirus: Inoculation with rhinovirus serotype 16</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo tablet once daily for 5 weeks&#xD;
Rhinovirus: Inoculation with rhinovirus serotype 16</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="17" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Professor Sebastian Johnston</name_or_title>
      <organization>Imperial College London</organization>
      <phone>+44 (0)20 7594 3764</phone>
      <email>s.johnston@imperial.ac.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

